R R

What Is Rystiggo?

Rystiggo is a prescription biologic medication containing rozanolixizumab-noli, a monoclonal antibody that blocks the neonatal Fc receptor. It is approved to treat generalized myasthenia gravis in adults who test positive for anti-acetylcholine receptor or anti-muscle-specific tyrosine kinase antibodies. Generalized myasthenia gravis is an autoimmune disorder that causes fluctuating skeletal muscle weakness. Rystiggo is administered as a subcutaneous infusion by a healthcare professional in six-week treatment cycles. It works by lowering circulating immunoglobulin G antibodies, including disease-related autoantibodies. Rystiggo can improve symptoms in eligible patients but does not permanently cure myasthenia gravis.

Link to This Resource Page

Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.

To display this...

What Is Rystiggo?

Rystiggo is a prescription biologic medication containing rozanolixizumab-noli, a monoclonal antibody that blocks the neonatal Fc receptor. It is approved to treat generalized myasthenia gravis in adults who test positive for anti-acetylcholine receptor or anti-muscle-specific tyrosine kinase antibodies. Generalized myasthenia gravis is an autoimmune disorder that causes fluctuating skeletal muscle weakness. Rystiggo is administered as a subcutaneous infusion by a healthcare professional in six-week treatment cycles. It works by lowering circulating immunoglobulin G antibodies, including disease-related autoantibodies. Rystiggo can improve symptoms in eligible patients but does not permanently cure myasthenia gravis.

read more about rystiggo ...

Copy this HTML:

Copy HTML Copied!

How Does Rystiggo Work?

Rystiggo blocks the neonatal Fc receptor, commonly called FcRn, which normally helps protect immunoglobulin G antibodies from degradation. Blocking this receptor increases the breakdown of circulating IgG, including autoantibodies that interfere with communication between nerves and muscles. In generalized myasthenia gravis, antibodies against acetylcholine receptors or muscle-specific tyrosine kinase can disrupt normal neuromuscular signaling. Reducing these antibodies can help improve muscle strength and daily function. Rystiggo does not directly repair damaged neuromuscular structures or prevent the immune system from producing new autoantibodies. Lower circulating IgG levels can also increase susceptibility to certain infections.

What Condition Does Rystiggo Treat?

Rystiggo is approved for generalized myasthenia gravis in adults who are positive for anti-acetylcholine receptor or anti-muscle-specific tyrosine kinase antibodies. Generalized myasthenia gravis can affect eye movements, facial muscles, speech, swallowing, breathing, and movement of the arms and legs. Symptoms may worsen with activity and improve after rest. Rystiggo is not approved for every form of muscle weakness or for patients without the specified antibody findings. A neurologist confirms the diagnosis and assesses disease severity, muscle strength, respiratory function, previous treatments, and infection history before initiating therapy. Additional treatment cycles depend on clinical response.

How Is Rystiggo Administered?

Rystiggo is administered by subcutaneous infusion once weekly for six weeks. The recommended dose depends on body weight. Patients weighing less than 50 kg receive 420 mg per infusion, those weighing 50 kg to less than 100 kg receive 560 mg, and patients weighing at least 100 kg receive 840 mg. Infusions are administered by trained healthcare personnel using the prescribed infusion system. Additional treatment cycles are determined by clinical evaluation. The safety of starting a subsequent cycle sooner than 63 days after the beginning of the previous cycle has not been established. Vaccination needs should be reviewed before each new cycle, and live vaccines are not recommended during treatment.

What Are the Side Effects and Warnings of Rystiggo?

Common adverse effects include headache, diarrhea, fever, nausea, and administration-site reactions. Rystiggo can increase susceptibility to infections because it lowers circulating IgG antibodies. Serious cases of aseptic meningitis have also been reported, with symptoms that may include severe headache, fever, neck stiffness, and sensitivity to light. Hypersensitivity reactions, including rash and angioedema, can occur. Treatment should be delayed in patients with active infections until they have resolved, and serious infections may require interruption. Clinicians monitor for infection symptoms and review vaccination needs. Persistent fever, severe headache, neck stiffness, facial swelling, or breathing difficulty requires prompt medical attention.

Common Questions About Rystiggo

Is Rystiggo the same as rozanolixizumab?

Yes. Rystiggo contains rozanolixizumab-noli, a monoclonal antibody that blocks the neonatal Fc receptor.

Can Rystiggo treat generalized myasthenia gravis?

Yes. Rystiggo is approved for adults with generalized myasthenia gravis who test positive for anti-AChR or anti-MuSK antibodies.

How many Rystiggo treatments are given in one cycle?

A treatment cycle consists of one subcutaneous infusion each week for six weeks. Additional cycles depend on clinical evaluation.

Can Rystiggo cause serious infections?

Yes. Rystiggo lowers circulating IgG levels and can increase infection risk. Patients should report persistent fever or other infection symptoms promptly.

References

DailyMed - RYSTIGGO (rozanolixizumab-noli) injection, solution. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3c0eb8c2-c042-4954-b451-3baa77f5e6d1. Date Accessed November 4, 2026.

Rozanolixizumab-noli. MedlinePlus. https://medlineplus.gov/druginfo/meds/a623040.html. Date Accessed November 4, 2026.

Rystiggo. European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/EPAR/rystiggo. Date Accessed November 4, 2026.

Rystiggo - Medicine Overview. European Medicines Agency. https://www.ema.europa.eu/en/documents/overview/rystiggo-epar-medicine-overview_en.pdf. Date Accessed November 4, 2026.

Safety and Efficacy of Rozanolixizumab in Patients With Generalised Myasthenia Gravis (MycarinG): A Randomised, Double-Blind, Placebo-Controlled, Adaptive Phase 3 Study. The Lancet Neurology. https://pubmed.ncbi.nlm.nih.gov/37059507/. Date Accessed November 4, 2026.